Guidelines for avoiding risks resulting from discontinuation of nucleos(t)ide analogues in patients with chronic hepatitis B (2012)

Kanzo/Acta Hepatologica Japonica

Volumn 53, Issue 4, 2012, Pages 237-242

  Tanaka, Eiji ^a   Matsumoto, Akihiro ^a   Suzuki, Yoshiyuki ^b   Kobayashi, Mariko ^b   Tanaka, Yasuhito ^c   Shinkai, Noboru ^c   Hige, Shuhei ^d   Yatsuhashi, Hiroshi ^e   Nagaoka, Shinya ^e   Chayama, Kazuaki ^f   Tsuge, Masataka ^f   Yokosuka, Osamu ^g   Imazeki, Fumio ^g   Nishiguchi, Shuhei ^h   Saito, Masaki ^h   Fujiwara, Kei ⁱ   Torii, Nobuyuki ^j   Hiramatsu, Naoki ^k   Karino, Yoshiyasu ^l  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TORANOMON HOSPITAL   (Japan)

^c NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^d HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

^f HIROSHIMA UNIVERSITY   (Japan)

^g CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h HYOGO COLLEGE OF MEDICINE   (Japan)

ⁱ NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

^j TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^k OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^l 5 N3E8   (Japan)

more..

Author keywords

Discontinuation of treatment; HBV cccDNA; Hepatitis B; Hepatitis relapse; Nucleos(t)ide analogue

Indexed keywords

NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE;

ARTICLE; HEPATITIS B; HUMAN; PRACTICE GUIDELINE; RISK REDUCTION; TREATMENT WITHDRAWAL;

EID: 84922685290     PISSN: 04514203     EISSN: 18813593     Source Type: Journal    
DOI: 10.2957/kanzo.53.237     Document Type: Article

References (18)

1. Ghany M, Liang TJ. Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. Gastroenterology 2007; 132: 1574-1585
2. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-1531
3. Matsumoto A, Tanaka E, Rokuhara A, et al. Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients. Hepatol Res 2005; 32: 173-184
4. Lok AS, Zoulim F, Locarnini S, et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007; 46: 254-265
5. Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126: 1750-1758
6. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-686
7. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73
8. Lim SG, Wai CT, Rajnakova A, et al. Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B. Gut 2002; 51: 597-599
9. Matsumoto A, Tanaka E, Suzuki Y, et al. Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B. Hepatol Res 2012; 42: 139-149
10. Chan HL, Wong VW, Tse AM, et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 2007; 5: 1462-1468
11. Moucari R, Lada O, Marcellin P. Chronic hepatitis B: back to the future with HBsAg. Expert Rev Anti Infect Ther 2009; 7: 633-636
12. Suzuki F, Miyakoshi H, Kobayashi M, et al. Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients. J Med Virol 2009; 81: 27-33
13. Tanaka E, Matsumoto A, Yoshizawa K, et al. Hepatitis B core-related antigen assay is useful for monitoring the antiviral effects of nucleoside analogue therapy. Intervirology 2008; 51 (suppl 1): 3-6
14. Wong DK, Tanaka Y, Lai CL, et al. Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection. J Clin Microbiol 2007; 45: 3942-3947
15. Matsumoto A, Tanaka E, Minami M, et al. Low serum level of hepatitis B core-related antigen indicates unlikely reactivation of hepatitis after cessation of lamivudine therapy. Hepatol Res 2007; 37: 661-666
16. Shinkai N, Tanaka Y, Orito E, et al. Measurement of hepatitis B virus core-related antigen as predicting factor for relapse after cessation of lamivudine therapy for chronic hepatitis B virus infection. Hepatol Res 2006; 36: 272-276
17. Rokuhara A, Matsumoto A, Tanaka E, et al. Hepatitis B virus RNA is measurable in serum and can be a new marker for monitoring lamivudine therapy. J Gastroenterol 2006; 41: 785-790
18. Hatakeyama T, Noguchi C, Hiraga N, et al. Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine. Hepatology 2007; 45: 1179-1186